Gastric , GEJ and Esophageal cancer studies recruiting patients need your help. Receive premium care & cutting edge treatments by enrolling in clinical trials today.

Top 10 Gastric Cancer Trials [2023 Studies] | Power

Gastric Cancer Clinical Trials

Gastric cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect clinical trial.

No Placebo-Only Group

The purpose of this study is to examine adherence to cardio-oncology consultation.

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

Cardiac Aggressive Risk Mitigation Plan for Cancer

You had a heart attack less than 6 months ago.

You are allergic to metal used in surgery or rubber materials.

You have severe or active scleroderma or systemic lupus erythematosus.

Assistant Professor, Radiation Oncology

Cardiac Aggressive Risk Mitigation Plan

The purpose of this study is to find out whether combining nivolumab, FOLFOX, and regorafenib may be a safe and effective treatment for people who have HER2-negative metastatic esophagogastric cancer.

Nivolumab is an antibody, like the proteins made by the immune system to protect the body from harm. Nivolumab blocks the protein PD-1 (programmed cell death receptor-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.

FOLFOX is a combination of three standard chemotherapy drugs (leucovorin, 5-fluorouracil, and oxaliplatin) commonly used to treat your type of cancer. The drugs work by damaging the DNA in cancer cells, which can cause the cells to stop growing and die.

Regorafenib is a type of drug called a tyrosine kinase inhibitor (TKI). This drug targets the tyrosine kinase protein found in or on the surface of cancer cells that the cells need to survive and grow. Blocking this protein may stop cancer cells from growing, or cause them to grow more slowly or to shrink.

The study researchers think that combining nivolumab, FOLFOX, and regorafenib may be a more effective treatment for HER2-negative metastatic esophagogastric cancer than the usual chemotherapy treatment(s) alone.

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Nivolumab + FOLFOX + Regorafenib for HER2-Negative Esophagogastric Cancer

You have already received treatment with regorafenib.

You have vitiligo or alopecia (hair loss).

You have cancer that has spread to your brain or the lining around your brain.

You have already received treatment with a specific kind of medication that targets proteins called PD-1, PD-L1, or PD-L2.

You have a lung condition called pneumonitis that is not caused by an infection and is currently active.

You have underactive thyroid or a condition called Hashimoto syndrome, but it is being treated with hormone replacement therapy.

Nivolumab

FOLFOX chemotherapy with oxaliplatin

Regorafenib

This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).

Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis

Intraperitoneal Docetaxel for Gastric Cancer

This study is evaluating whether a combination of chemotherapy and a drug called docetaxel may help treat gastric cancer.

You have previously received a transplant using cells from another person.

You have cancer that has spread to your brain or the lining of your brain.

You have gastric cancer that affects the upper part of the stomach near the esophagus or the second part of the small intestine called the duodenum.

You have any known heart problems that are not compatible with the mFOLFOX6 treatment guidelines.

You are allergic to any of the ingredients in docetaxel or mFOLFOX6.

You are willing to have a device called an intraperitoneal port placed in your body for the study.

You have received radiation therapy in your pelvic or abdominal area.

You have had a previous surgery that caused thick scar tissue inside your abdomen.

You have another type of cancer that is getting worse or needs ongoing treatment, except for certain types of skin or cervical cancer that can be cured.

Gastric Cancer Clinical Trials

Cardiac Aggressive Risk MitigAtion Planfor Cancer

Nivolumabfor Esophageal Cancer

Intraperitoneal Docetaxelfor Peritoneal Carcinomatosis